ASCO highlights, EXERCISE proven again

pete43lost_at_sea Member Posts: 3,900 Member


Long-Term Tamoxifen Benefit for Breast Cancer Confirmed 
Anna Azvolinsky, PhD 
Women diagnosed with estrogen-receptor (ER)-positive breast cancer who took tamoxifen for 10 years as adjuvant therapy had lower risk of late recurrence and lower risk of death compared to those who took the drug for 5 years. These results corroborate the findings of the international ATLAS trial.
Sulforaphane in Prostate Cancer Found Worthy of Further Investigation 
Michael Kaufman
In a small trial, treatment with 200 µmol per day of sulforaphane for 20 weeks was "feasible, safe," and inhibited histone deacetylase (HDAC) function in a single-arm study of 20 patients who had non-castrate biochemical (PSA)-recurrence of prostate cancer despite surgery or radiation, results that could form the "basis for dose-escalation studies of sulforaphane."
Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
Anna Azvolinsky, PhD
A large study shows that middle-age men engaged in lots of cardiovascular exercise have a reduced risk of developing and dying from lung and colorectal cancer.
DNR Completion at End of Life Influenced by Perception of Caregiver Support 
Leah Lawrence
Results of a new study indicated that patients with terminal cancer are more likely to have completed a do-not-resuscitate order when they prefer, and believe that their caregiver prefers, comfort at the end of life.
Pomalidomide New Standard of Care in Heavily Pretreated Relapsed Multiple Myeloma 
Leah Lawrence 
Pomalidomide in combination with low-dose dexamethasone had a highly significant benefit on progression-free survival and overall survival compared with single-agent high-dose dexamethasone in patients with relapsed or refractory multiple myeloma, according to updated results of the MM-03 trial presented at the ASCO 2013 Annual Meeting.
For Painful Bone Mets, Single Fraction Irradiation Noninferior to Multiple-Fraction Therapy 
Leah Lawrence
The use of a single 8 Gy fraction of re-irradiation for the treatment of painful bone metastases was noninferior to multiple fractions, according to the results of the NCIC CTG SC.20 trial presented at the ASCO 2013 Annual Meeting in Chic